Hongjie Pei

Title: Innovations of Hongjie Pei in Gene Therapy

Introduction

Hongjie Pei is a prominent inventor based in Beijing, China. He has made significant contributions to the field of gene therapy, particularly in the treatment of retinal diseases. His innovative work has led to the development of a unique vector that holds promise for treating Bietti's crystalline dystrophy.

Latest Patents

Hongjie Pei holds a patent for a vector and method for treating Bietti's crystalline dystrophy. The patent describes a vector comprising a polynucleotide encoding CYP4V2 and a promoter operably linked to this polynucleotide. This vector demonstrates a good expression effect, high expression speed, and stable expression intensity. The application also includes cells, pharmaceutical compositions, and kits that utilize the vector, along with methods for treating, alleviating, and preventing diseases associated with retinal pigment epithelium (RPE) atrophy.

Career Highlights

Pei is associated with Chigenovo Co., Ltd., where he continues to advance his research and development efforts. His work is pivotal in the ongoing quest to find effective treatments for retinal disorders, showcasing his commitment to improving patient outcomes.

Collaborations

Hongjie Pei has collaborated with notable colleagues, including Liping Yang and Shaohong Chen. These partnerships enhance the research environment and contribute to the innovative solutions being developed in the field.

Conclusion

Hongjie Pei's contributions to gene therapy, particularly through his patent for a vector aimed at treating Bietti's crystalline dystrophy, highlight his role as a leading inventor in the field. His work continues to inspire advancements in medical treatments for retinal diseases.